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Abstract: Matrix metalloproteinase 2 (MMP-2) is able to degrade type IV collagen, and thus plays a key role
in the migration of tumor cells. MMP-2 activity is inhibited by its tissue inhibitor (TIMP-2). The imbalance
between MMPs and TIMPs may facilitate progression of cancer cells. The aim of this study was to compare the
clinical importance of MMP-2 and TIMP-2 to that of classical tumor markers, namely carcinoembryonic anti-
gen (CEA) and carbohydrate antigen (CA 19-9) in the diagnosis of gastric cancer (GC) by calculating the
diagnostic criteria and estimating the levels of MMP-2, TIMP-2, CEA and CA 19-9 in GC patients in relation
to clinicopathological features of cancer. We found that serum levels of MMP-2 and TIMP-2 were significantly
lower, whereas serum tumor markers were higher, in GC patients than in healthy subjects. Moreover, concen-
trations of TIMP-2 and CEA correlated with gastric wall infiltration, while CA 19-9 levels correlated with
gastric wall infiltration and the presence of nodal metastasis. None of the proteins tested was found to be an
independent prognostic factor for GC patients’ survival. The percentage of true positive results of TIMP-2
(61%) was higher than those of MMP-2 (54%) and the classical tumor markers CEA (21%) and CA 19-9
(31%). The highest diagnostic sensitivity was observed for the combined use of TIMP-2 with MMP-2 (77%).
The results suggest the greater importance of serum MMP-2 and TIMP-2 than of the classical tumor markers
CEA and CA 19-9 in the diagnosis of GC. But this issue requires further investigation. (Folia Histochemica et
Cytobiologica 2011; Vol. 49, No. 1, pp. 125–131)
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Introduction
The degradation of extracellular matrix (ECM) is
a crucial step in tumor progression, aggressive growth
and metastases [1, 2]. The invasion of cancer cells
within the basement membrane depends on matrix
metalloproteinases (MMPs) and their inhibitors’ ac-
tivities [1, 3].
Matrix metalloproteinases (MMPs) are a family
of extracellular zinc endoproteases capable of degra-
ding all the ECM components [3]. MMPs are produced
by tumor cells, so they may be associated with tumor
progression including invasion, migration, angiogene-
sis and metastasis [1, 2, 4, 5]. Among the MMPs, ma-
trix metalloproteinase 2 (MMP-2) and matrix metal-
loproteinase 9 (MMP-9) play important roles in the
migration of malignant cells, because of their ability
to degrade type IV collagen [6]. The mechanisms of
activation of these enzymes are different.
MMP-9 modulates permeability of the vascular en-
dothelium, whereas MMP-2 promotes cleavage of ex-
tracellular matrix proteins and is intensively expressed
by tumor and stromal components of cancer [7].
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The activity of MMP-2 is regulated at several le-
vels, including transcriptional, post-transcriptional
and post-translational levels, as well as via their en-
dogenous inhibitors — TIMPs (tissue inhibitor of
matrix metalloproteinase) [8, 9]. Moreover, MMP-2,
either in latent or activated form, is able to produce
complexes with TIMP-2. It has been found that tis-
sue inhibitor of matrix metalloproteinase 2 (TIMP-2)
is more than ten times more effective in inhibiting
MMP-2 activity than tissue inhibitor of matrix metal-
loproteinase 1 (TIMP-1) [8–11]. Several studies have
established the role of MMP-2 and TIMP-2 and MMP-
2/TIMP-2 complex in the growth and progression of
many types of cancer, including colorectal [12, 13],
pancreatic [14], lung [15] and gastric cancer [16–18].
Gastric cancer (GC) remains a major cause of mor-
tality and morbidity worldwide [19]. The rapid invasion
and metastasis of tumor cells are responsible for poor
prognosis [20]. The high expression of MMP-2 and
TIMP-2 in GC tissues has been determined in several
studies [16, 17, 21, 22]. It has been shown that MMP-2
expression correlates with clinicopathological features
of GC, such as tumor stage, depth of tumor invasion
and the presence of lymph node and distant metastas-
es, while immunoreactivity of TIMP-2 correlates with
tumor differentiation and the presence of distant me-
tastases [16–18, 21]. Moreover, Kubben et al. [22] es-
tablished the importance of MMP-2 as an independent
prognostic factor for the survival of GC patients.
However, to the best of our knowledge, this is the
first study assessing diagnostic criteria for MMP-2 and
TIMP-2 in the sera of GC patients in comparison with
the classical tumor markers, carcinoembryonic anti-
gen (CEA) and carbohydrate antigen (CA 19-9).
The aim of the current study was to compare the
clinical importance of serum MMP-2 and its inhibi-
tor (TIMP-2) with classical tumor markers (CEA and
CA 19-9) in the diagnosis of GC by calculating the
diagnostic criteria, such as diagnostic sensitivity and
specificity (the percentage of true positive and nega-
tive results), and positive and negative predictive va-
lues for all the proteins tested. In addition, we deter-
mined MMP-2, TIMP-2 and classical tumor marker
levels in the sera of GC patients in relation to clinico-
pathological features of cancer, including tumor stage,
gastric wall infiltration, and the presence of lymph node
and distant metastasis as well as patients’ survival.
Material and methods
Patients
The study included 100 patients with GC and 91
healthy subjects. Eighty-nine of the GC patients (27
women and 73 men, aged 27–83 years) underwent
surgical tumor resection in the Second General Sur-
gery Department of the Medical University Hospital
in Bialystok, while the other 11 patients had non-re-
sectable tumors. The control group comprised 60
women and 31 men, aged 21–65 years. The GC pa-
tients were observed over a period of four years. There
were no significant differences between female and
male subjects in GC patients and control groups.
However the differences were statistically significant
for age of patients in both analyzed groups. The di-
agnosis of GC was confirmed by microscopic exami-
nation of the tumor samples obtained during gastros-
copy and/or surgery. The staging of cancer was based
on TNM (tumor-nodulus-metastases) classification,
according to the 5th International Union Against Can-
cer [23]. For statistical analysis, the GC patients were
divided into three groups: 27 cancer patients in stage
I + II, 31 patients in stage III, and 42 patients in
stage IV. They were also sub-divided into three groups
depending on gastric wall infiltration (T1 + T2, T3,
and T4), two groups depending on nodal involvement
(N0, N1 + N2 + N3), and two groups depending on
the presence of distant metastases (M0 and M1). Six-
ty-six patients had intestinal type gastric adenocarci-
noma by Lauren classification, whereas 34 patients
had diffuse type GC. The study was approved by the
Local Ethics Committee and all the patients gave in-
formed consent.
Biochemical analyses
Blood samples from all the patients were drawn be-
fore treatment. All the sera were separated within an
hour of blood collection and stored at –80°C until
assayed.
Serum levels of MMP-2 and TIMP-2 were mea-
sured using enzyme-linked immunosorbent assay kits
(ELISA) (R&D Systems, Abingdon, UK) according
to the manufacturer’s instructions. The serum sam-
ples were diluted 10-fold before determination for
MMP-2, and 50-fold for TIMP-2. The manufacturer
of assay kits described the intra-assay coefficient of
variation (CV%) for MMP-2 as 5.8% at mean con-
centration of 18.9 ng/mL, SD = 1.1, and for TIMP-2
as 4.4% at a mean level of 1.23 ng/mL with SD =
= 0.054. Serum concentrations of CEA and CA 19-9
were measured by microparticle enzyme immunoas-
say kits (MEIA) (Abbott, Chicago, IL, USA). The
intra-assay CV% for CEA was reported by the manu-
facturer of the assay kits to be 4.9% at a mean con-
centration of 2.2 ng/mL, SD = 0.11 and the intra-
assay CV% for CA 19-9 — 4.7% at a mean concen-
tration of 38.2 U/mL, SD = 1.80.
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The reference cut-off values for classical tumor
markers (the 95th percentile), 4.0 ng/mL for CEA and
30.0 U/mL for CA 19-9, were established previously
in our department by examining blood sera of healthy
volunteers [24]. The cut-off values for serum MMP-2
(188 ng/mL) and TIMP-2 (85 ng/mL) levels correspond
to the highest accuracy (minimal false-negative and
false-positive results) and were determined using Mi-
crosoft Office Excel software. The positive results of
MMP-2 and TIMP-2 are below cut-off values.
Statistical analysis
The levels of MMP-2 and classical tumor markers
CEA and CA 19-9 did not follow a normal distribu-
tion based on preliminary statistical analysis (c 2 test).
Consequently, nonparametric statistical analyses were
used. The Mann–Whitney U-test was employed to
compare the two groups, while differences between
more than two groups were compared using ANO-
VA on ranks (Kruskal–Wallis tests). The post hoc
Dwass-Steel-Critchlow-Fligner test was conducted to
assess which groups were different, if significant dif-
ferences were found. Data are presented as the me-
dian and range. The differences were considered sta-
tistically significant when p < 0.05. The Kaplan–
–Meier method was used for the calculation of the
survival curves. The log-rank test for univariate ana-
lyses of survival and the Cox proportional hazards
model for multivariate analyses were employed.
Moreover, we calculated diagnostic criteria, such as
percentage of true positive and negative results, posi-
tive and negative predicted values for MMP-2, TIMP-
2 and tumor markers. Statistical analyses were car-
ried out using the STATISTICA 5.1 PL program (Stat-
Soft Inc., Tulsa, OK, USA). Diagnostic criteria were
calculated using Med-Calc statistical software (Med-
-Calc Software, Mariakerke, Belgium) and Microsoft
Office Excel.
Results
The median and range of MMP-2 and TIMP-2 levels
and classical tumor markers (CEA and CA 19-9) in
GC and healthy subjects (the control group) are pre-
sented in Tables 1 and 2. The levels of MMP-2 and
TIMP-2 were significantly lower, whereas CEA and
CA 19-9 were higher, in GC patients compared to
healthy subjects.
According to the tumor stage, based on TNM clas-
sification, the MMP-2 levels were lower in stages I +
+ II and IV compared to stage III, while concentra-
tions of TIMP-2 were lower in stages III and IV than
in stages I + II, although these differences were not
statistically significant (Table 1). The levels of CEA
and CA 19-9 increased with more advanced GC stage
and were highest in stage IV; however, the differ-
ences were found to be significant only for CA 19-9
(p = 0.049) (Table 2).
Serum levels of all the proteins tested varied ac-
cording to the clinicopathological features of GC,
such as gastric wall infiltration, the presence of lymph
node and distant metastasis. Statistically significant
differences were found between the serum levels
of TIMP-2 (p = 0.002), CEA (p = 0.018), CA 19-9
Table 1. Serum levels of MMP-2 and TIMP-2 in GC patients in relation to clinicopathological features of tumor
n MMP-2 [ng/mL] TIMP-2 [ng/mL]
Median Range      p        Median Range p
Group tested Gastric cancer 100 184 118 500 0.006* 79 53 149 < 0.001*
Healthy controls 91 205 118 384 94 54 162
Tumor stage I + II 27 178 132 500 NS 88 62 149 NS
III 31 195 134 394 78 63 123
IV 42 184 118 499 79 53 106
Gastric wall infiltration T1 + T2 24 182 136 500 NS 90 63 149 0.002*
T3 40 179 120 387 76A 53 117
T4 36 189 118 499 85 58 123
Nodal involvement N0 25 175 132 495 NS 83 62 149 NS
N1 + N2 + N3 75 187 118 500 78 53 133
Distant metastases M0 65 185 132 500 NS 79 62 149 NS
M1 35 183 118 499 80 53 106
*Statistically significant when p < 0.05; NS — not statistically significant; A — statistically significant when compared to T1 + T2 group
in Dwass–Steel–Critchlow–Fligner post hoc test
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(p = 0.034) and gastric wall infiltration (T factor), as
well as between CA 19-9 (p = 0.001) concentrations
and nodal involvement (N factor). Moreover, TIMP-2
levels were significantly lower in the T3 subgroup
compared to patients in the T1 + T2 group (Table 1),
while CEA and CA 19-9 were significantly higher in
the T4 subgroup in compared to the T1 + T2 sub-
group (Table 2).
The Kaplan–Meier method was used to assess the
relationship between survival of GC patients and pro-
teins tested levels. Univariate log-rank analysis
showed that tumor size (p = 0.004), the presence of
nodal involvement (p = 0.003) and distant metasta-
ses (p = 0.001), as well as the levels of CEA (p =
= 0.007) and CA 19-9 (p = 0.008), were significant
factors affecting overall survival. However, multivari-
ate regression analysis using Cox’s proportional haz-
ards model failed to establish the significance of the
classical tumor markers as independent prognostic
factors for the survival of GC patients.
The percentage of true positive results (diagnos-
tic sensitivity) of proteins tested is presented in Figu-
re 1. The diagnostic sensitivity of TIMP-2 (61%) was
higher than that of MMP-2 (54%) and double that
of classical tumor markers CEA and CA 19-9 (re-
spectively: 21% and 31%). The highest percentage
of true positive results was observed for combined
use of TIMP-2 with MMP-2 (77%) compared to the
diagnostic sensitivity of tumor markers (Figure 1).
The percentage of true negative results (diagnostic
specificity) for TIMP-2 (73%) and MMP-2 (68%)
levels was lower than those for classical tumor mark-
ers, CEA (98%), and CA 19-9 (97%), similarly for
positive predictive value. However, negative predic-
tive value was higher for TIMP-2 (63%) and MMP-
2 (57%) compared to classical tumor markers. The
highest negative predictive value was observed for
combined use of TIMP-2 with MMP-2 or CA 19-9
(68%).
Discussion
Matrix metalloproteinase-2 is a zinc-dependent pro-
tease released from a cell as a zymogen. This enzyme
requires extracellular post-translational cleavage to
gain biological activity [9, 11, 25]. MMP-2 is found in
various cells, including normal myocytes and vascu-
lar cells, and therefore may play a role in cardiac re-
modeling, heart tube formation and angiogenesis [26,
27]. Some clinical investigations have indicated that
MMP-2 is an important protease implicated in the
proteolytic regulation of various intracellular proteins
in myocardial oxidative stress injury [9, 26]. This en-
zyme is also produced by tumor cells and may facili-
tate the migration of malignant cells because of its
ability to degrade type IV collagen of extracellular
matrices and basal membranes [6, 21]. MMP-2 activity
is inhibited by its tissue inhibitors, including TIMP-2
[8, 21]. The imbalance between MMPs and their in-
hibitors may facilitate progression of cancer cells [5, 8].
It has been shown that increased MMP-2 and TIMP-2
expression plays a key role in invasion and metastases
of several types of cancer, such as colorectal [12, 13],
pancreatic [14] and gastric cancer [16–18, 28].
The objective of the current study was to investi-
gate the differences between diagnostic criteria, in-
Table 2. Serum levels of classic tumor markers in GC patients in relation to clinicopathological features of tumor
n                       CEA [ng/mL]                        CA 19-9 [U/mL]
Median Range      p        Median Range p
Group tested Gastric cancer 100 1.4 0.1 620.0 < 0.001* 6.9 0.0 50000.0 < 0.001*
Healthy controls 91 0.8 0.1 11.4 0.8 0.0 53.0
Tumor stage I + II 27 1.2 0.3 6.9 NS 3.4A 0.0 431.0 0.049*
III 31 1.2 0.3 120.3 7.0 0.0 2169.0
IV 42 2.0 0.1 620.0 16.0 0.0 50000.0
Gastric wall infiltration T1 + T2 24 1.1 0.3 11.9 0.018* 3.6 0.0 339.0 0.034*
T3 40 1.2 0.1 120.3 8.7 0.0 10880.0
T4 36 2.1B 0.6 620.0 16.0B 0.0 50000.0
Nodal involvement N0 25 1.4 0.1 6.9 NS 2.0 0.0 431.0 0.001*
N1 + N2 + N3 75 1.7 0.3 620.0 11.7 0.0 50000.0
Distant metastases M0 65 1.3 0.3 120.3 NS 5.8 0.0 4005.0 NS
M1 35 1.9 0.1 620.0 8.8 0.0 50000.0
*Statistically significant when p < 0.05; NS — not statistically significant; A — statistically significant when compared to stage IV in Dwass–Steel–
–Critchlow–Fligner post hoc test; B — statistically significant when compared to T1 + T2 group in Dwass–Steel–Critchlow–Fligner post hoc test
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cluding diagnostic sensitivity and specificity (the per-
centage of true positive and negative results), posi-
tive and negative predictive values for MMP-2, TIMP-
2 and classical tumor markers (CEA and CA 19-9) as
well as serum levels of all the proteins tested in rela-
tion to clinicopathological features of the tumor as
well as GC patients’ survival.
We found the serum levels of MMP-2 and TIMP-2
were significantly lower in the GC patients group
than in healthy subjects. Our results agree with the
findings of Waas et al. [29], who revealed that the
levels of precursor form of MMP-2 (proMMP-2)
were significantly lower in the plasma of patients
with colorectal cancer (CRC) than in healthy con-
trols. Contradictory results were found in the study
of Endo et al. [30], who indicated that serum as well
as plasma levels of proMMP-2 in GC patients were
significantly higher compared to healthy individ-
uals. Moreover, Kubben et al. [22] demonstrated
that MMP-2 expression was significantly increased
in GC tissue compared to normal gastric mucosa.
We found the serum concentrations of classical tu-
mor markers were significantly higher in GC pa-
tients compared to the control group. This was sim-
ilar to our previous study, where we showed that
the CEA levels were significantly higher in GC pa-
tients than in healthy subjects [31]. Our current re-
sults indicate that the concentrations of MMP-2
were lower in stage IV compared to stage III, where-
as TIMP-2 levels were lower in more advanced tu-
mor stages than in early stages (I + II). Similar re-
sults were obtained by Alakus et al., who suggested
that aggressive forms of GC are associated with low
TIMP-2 expression [21].
Serum concentrations of MMP-2, TIMP-2 and
classical tumor markers varied according to clinico-
pathological features of GC, such as gastric wall in-
filtration, the presence of lymph nodes and distant
metastases. Serum TIMP-2 levels were significantly
lower in the T3 subgroup compared to patients in
the T1 + T2 group. However, we did not find statisti-
cally significant differences between the serum levels
of MMP-2 and gastric wall infiltration (T factor).
Contradictory results were shown by Shim et al. [1],
who failed to establish any significant differences
between expression of TIMP-2 and clinicopathologi-
cal parameters of GC.
Similarly as in our findings, Endo et al. [30] were
unable to demonstrate a significant association be-
tween serum proMMP-2 concentrations and gastric
wall infiltration. However,  several studies have indi-
cated that expression of MMP-2 is positively corre-
lated with depth of tumor invasion, lymphatic node
and distant metastases, while the intensity of TIMP-2
staining is positively correlated with the presence of
distant metastasis [16–18, 21].
Our current study assessed the association bet-
ween the survival of GC patients and the serum clas-
sical tumor markers concentrations using the Ka-
plan–Meier method, although we did not detect any
tendency that would point to MMP-2 and TIMP-2
as prognostic factors for GC patients’ survival. Our
observations are in line with the findings of Alakus
et al. [21], who indicated that high expression of
MMP-2 in GC tissue was associated with poor prog-
nosis, but not as an independent prognostic factor,
while TIMP-2 showed no correlation with the GC
patients’ survival, in a similar way to CEA levels in
our previous study [31]. However, Kubben et al. [22]
proved the significance of enhanced tumor MMP-2
levels as an independent prognostic factor of the
survival of GC patients as well as plasma TIMP-1
concentrations, which was confirmed in our previ-
ous study [31].
Figure 1. The percentage of true positive results of MMP-2, TIMP-2 and classic tumor markers in GC patients
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The percentage of true positive results of TIMP-2
(61%) was higher than those of MMP-2 (54%) and
had twice the diagnostic sensitivity of classical tumor
markers. The highest frequency of true positive re-
sults was observed for combined use of TIMP-2 with
MMP-2 (77%). The percentage of true positive re-
sults established in the present paper was slightly lo-
wer than those obtained in our previous data, where
we calculated the diagnostic sensitivity of other MMPs
and their inhibitors in GC patients, including MMP-9
(60%) and TIMP-1 (78%) [31].
However, the frequency of true positive results
of MMP-2 and TIMP-2 assessed in the current pa-
per was higher than those of other biomarkers use-
ful in GC diagnosis — hematopoietic growth fac-
tors (HGFs), such as granulocyte-colony stimulating
factor (G-CSF) (36%), granulocyte-macrophage
colony stimulating factor (GM-CSF) (29%), stem
cell factor (SCF) (19%) and macrophage colony
stimulating factor (M-CSF) (10%) [32]. The percen-
tage of true negative results obtained in the present
data for TIMP-2 (73%) and MMP-2 (68%) levels
was lower than those for classical tumor markers,
CEA (98%) and CA 19-9 (97%) as well as for M-CSF
(95%), SCF (94%), G-CSF (92%), and GM-CSF
(82%) assessed in our previous paper [32].
In conclusion, to the best of our knowledge, the
present study is the first to assess serum levels of
MMP-2 and its tissue inhibitor (TIMP-2) compared
to classical tumor markers in relation to clinico-
pathological features of GC, including tumor stage,
gastric wall infiltration, the presence of lymph node
and distant metastasis as well as patients’ survival.
Moreover, the current study is the first to compare
the diagnostic criteria of MMP-2 and TIMP-2 with
classical tumor markers in this cancer. We found that
serum levels of MMP-2 and TIMP-2 were signifi-
cantly lower, but concentrations of classical tumor
markers were higher, in GC patients than in healthy
subjects. Additionally, serum TIMP-2, CEA and CA
19-9 correlated with gastric wall infiltration. None
of the proteins tested was found to be an indepen-
dent prognostic factor for GC patients’ survival. The
percentage of true positive results (diagnostic sen-
sitivity) of TIMP-2 (61%) and MMP-2 (54%) were
higher than those for the tumor markers CEA (21%)
and CA 19-9 (31%).
These findings suggest that serum MMP-2 and
TIMP-2 are more useful than classical tumor mar-
kers in the diagnosis of gastric cancer. However, our
paper is one of the first studies of the serum levels of
MMP-2 and TIMP-2 in GC patients, and therefore
further investigation seems to be necessary.
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